EP2131812A2 - Gaseous mixture containing o2 and n2o for preventing or reducing hyperalgesia - Google Patents
Gaseous mixture containing o2 and n2o for preventing or reducing hyperalgesiaInfo
- Publication number
- EP2131812A2 EP2131812A2 EP08788075A EP08788075A EP2131812A2 EP 2131812 A2 EP2131812 A2 EP 2131812A2 EP 08788075 A EP08788075 A EP 08788075A EP 08788075 A EP08788075 A EP 08788075A EP 2131812 A2 EP2131812 A2 EP 2131812A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- hyperalgesia
- gaseous mixture
- nitrous oxide
- oxygen
- mixture according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000004454 Hyperalgesia Diseases 0.000 title claims abstract description 20
- 208000035154 Hyperesthesia Diseases 0.000 title claims abstract description 20
- 239000008246 gaseous mixture Substances 0.000 title claims abstract description 20
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims abstract description 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 18
- 239000001301 oxygen Substances 0.000 claims abstract description 18
- 239000001272 nitrous oxide Substances 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 239000007789 gas Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 230000002980 postoperative effect Effects 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 230000001143 conditioned effect Effects 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000036407 pain Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003537 desflurane Drugs 0.000 description 1
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940051877 other opioids in atc Drugs 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B21/00—Nitrogen; Compounds thereof
- C01B21/20—Nitrogen oxides; Oxyacids of nitrogen; Salts thereof
- C01B21/22—Nitrous oxide (N2O)
Definitions
- the present invention relates to a gaseous mixture containing oxygen (O 2 ) and nitrous oxide (N 2 O) for preventing or minimizing / treating post-operative hyperalgesia in humans or animals.
- anesthetic products which are commonly used in anesthesia, such as sevoflurane, desflurane, fentanyl, remifentamyl or other opioids ...
- postoperative hyperalgesia which result in an increase in the pain sensitivity of the patients, after the operation and / or the phase diagnosis during which the patient was anesthetized.
- This postoperative hyperalgesia generates greater sensitivity to pain whatever the origin or location, that is to say whether it is localized or not in the treated area during the operation or the phase diagnosis.
- This effect is noticeable for a long period, including up to 1 year, and leads to a decrease in the quality of life of people since they will be more sensitive to pain during all this time.
- An object of the invention is to prevent or at least to slow down or reduce the appearance of this harmful phenomenon of postoperative hyperalgesia in patients by proposing an effective drug capable of curbing or reducing the onset of this phenomenon. phenomenon.
- a solution according to the invention is a gaseous mixture containing oxygen (O 2 ) and nitrous oxide (N 2 O) intended to prevent or minimize / treat postoperative hyperalgesia in humans or humans. animal, wherein the proportion of nitrous oxide is between 5 and 15% by volume.
- the term "man” must be understood in its most general sense, namely "human being”, which includes men, women and children.
- the gaseous mixture of the invention may comprise one or more of the following characteristics:
- the gaseous mixture containing oxygen and nitrous oxide according to the invention is usable as an inhalable medicament for preventing hyperalgesia in humans.
- the invention also relates to the use of a gaseous mixture according to the invention for producing an inhalable medicament for preventing or reducing hyperalgesia in humans, in particular when the hyperalgesia is of the postoperative type. , in particular induced by at least one opioid.
- the gaseous mixture of the invention is administered by inhalation to the patient, for example by means of a mask fed with gas or by means of a respiratory ventilator and this administration is done during the anesthesia phase of said patient.
- the invention thus also relates to a method of anesthesia of a patient comprising the following steps: a) administering to a patient an opioid anesthetic or analgesic substance so as to obtain anesthesia of said patient by at least said substance, b) maintain the patient under-anesthesia for a given duration, in particular during at least a part of the diagnosis phase and / or the operating phase of said patient, c) to administer to said patient, before, during and / or after step b), a gaseous mixture of O 2 and N 2 O according to the invention, in particular a gaseous mixture containing oxygen (O 2 ) and nitrous oxide (N 2 O) in a proportion of nitrous oxide included between 5 and 15% by volume.
- a gaseous mixture of O 2 and N 2 O according to the invention, in particular a gaseous mixture containing oxygen (O 2 ) and nitrous oxide (N 2 O) in a proportion of nitrous oxide included between 5 and 15% by volume.
- a gas source containing a gas mixture of O 2 and N 2 O pre-conditioned according to the invention, a source of N 2 O and a source of oxygen and the mixture N 2 O / O 2 in the proportions Desired according to the invention will be directly within said fan by mixing said gases.
- the desired gas mixture will be defined by adjusting the fan and it is the latter which will automatically mix by taking the quantities of pure gas from each of the gas sources, such as gas cylinders or a network of pipes, or both, connected to it.
- the effectiveness of the gaseous mixture according to the invention was evaluated by administering to a gaseous mixture containing 12.5% by volume of nitrous oxide, 50% oxygen and the rest of nitrogen to a group of 20 healthy volunteers (test B ) having received a volatile anesthetic, for example remifentamyl, during a biomedical research involving a model of electrical stimulation for 2 h, reproducing the postoperative hyperalgesia.
- a volatile anesthetic for example remifentamyl
- the gas mixture N2O / O2 / N2 is administered by inhalation to persons by means of a breathing mask connected to a gas mixture source, for example a gas cylinder containing the gaseous mixture.
- test A a placebo (a gas formed of 50% oxygen and 50% nitrogen) was administered to the same group of 20 healthy volunteers (test A) following strictly the same procedure.
- Test A and Test B undergo electrical stimulation to assess their level of sensitivity to pain.
- the hyperalgesia of these individuals was evaluated throughout the duration of the electrical stimulation (10 measurements for 2 hours).
- test A After comparing the results obtained, in test A, healthy volunteers have a greater sensitivity to pain than in test B, when they received the N2O / O2 mixture of the invention.
- gaseous mixture N 2 O / O 2 of the invention one can effectively fight against the adverse effect of opioid-induced postoperative hyperalgesia, by administration to the patient's airways of said inhalable gas mixture.
- N 2 O / O 2 gas mixture of the invention N 2 O / O 2 may be administered before, during and / or after the opioid anesthesia phase, preferably before, during and after the anesthesia phase.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a gaseous mixture containing oxygen and nitrous oxide in a nitrous oxide proportion of between 5 and 15 vol. %, that can be used for producing a drug for preventing or reducing hyperalgesia in human beings or animals, in particular a post-operation opioid-induced hyperalgesia.
Description
Mélange gazeux à base de O? et de N?O destiné à prévenir ou à diminuer une hyperalgésie Gaseous mixture based on O? and N? O for preventing or decreasing hyperalgesia
La présente invention porte sur un mélange gazeux contenant de l'oxygène (O2) et du protoxyde d'azote (N2O) destiné à prévenir ou à minimiser/traiter les hyperalgésies post-opératoires chez l'homme ou l'animal.The present invention relates to a gaseous mixture containing oxygen (O 2 ) and nitrous oxide (N 2 O) for preventing or minimizing / treating post-operative hyperalgesia in humans or animals.
Durant les anesthésies générales, il est habituel d'administrer des hypnotiques volatiles ou intraveineux aux patients, ou des substances analgésiques intraveineuses ou opioïdes.During general anesthesia, it is usual to administer volatile or intravenous hypnotics to patients, or intravenous or opioid analgesic substances.
Par exemple, on peut citer les produits anesthésiques suivants qui sont couramment utilisés en anesthésie, tels que sevoflurane, desflurane, fentanyl, remifentamyl ou autres opioïdes...For example, there may be mentioned the following anesthetic products which are commonly used in anesthesia, such as sevoflurane, desflurane, fentanyl, remifentamyl or other opioids ...
Or, il a été constaté en pratique que cela induit des effets indésirables chez les patients, appelés « hyperalgésie post-opératoire », qui se traduisent par une augmentation de la sensibilité à la douleur des patients, après l'opération et/ou la phase de diagnostic durant laquelle ou lesquelles le patient a été anesthésie.However, it has been found in practice that this induces adverse effects in patients, called "postoperative hyperalgesia", which result in an increase in the pain sensitivity of the patients, after the operation and / or the phase diagnosis during which the patient was anesthetized.
Cette hyperalgésie post-opératoire engendre une plus grande sensibilité à la douleur quelle qu'en soit l'origine ou la localisation, c'est-à-dire qu'elle soit localisée ou non dans la zone traitée durant l'opération ou la phase de diagnostic.This postoperative hyperalgesia generates greater sensitivity to pain whatever the origin or location, that is to say whether it is localized or not in the treated area during the operation or the phase diagnosis.
Cet effet est notable durant une période longue, pouvant aller notamment jusqu'à 1 an, et conduit à une diminution de la qualité de vie des personnes puisque celles-ci seront plus sensibles à la douleur durant tout ce temps.This effect is noticeable for a long period, including up to 1 year, and leads to a decrease in the quality of life of people since they will be more sensitive to pain during all this time.
Un but de l'invention est de permettre d'éviter ou au moins de freiner ou diminuer l'apparition de ce phénomène néfaste d'hyperalgésie post-opératoire chez les patients en proposant un médicament efficace apte à freiner ou diminuer l'apparition de ce phénomène.An object of the invention is to prevent or at least to slow down or reduce the appearance of this harmful phenomenon of postoperative hyperalgesia in patients by proposing an effective drug capable of curbing or reducing the onset of this phenomenon. phenomenon.
Une solution selon l'invention est un mélange gazeux contenant de l'oxygène (O2) et du protoxyde d'azote (N2O) destiné à prévenir ou à minimiser/traiter une hyperalgésie post-opératoires chez l'homme ou l'animal, dans lequel la proportion de protoxyde d'azote est comprise entre 5 et 15 % en volume.A solution according to the invention is a gaseous mixture containing oxygen (O 2 ) and nitrous oxide (N 2 O) intended to prevent or minimize / treat postoperative hyperalgesia in humans or humans. animal, wherein the proportion of nitrous oxide is between 5 and 15% by volume.
Dans le cadre de l'invention, le terme « homme » doit être compris dans son sens le plus général, à savoir « être humain », ce qui englobe donc les hommes, les femmes et les enfants.
Selon le cas, le mélange gazeux de l'invention peut comprendre l'une ou plusieurs des caractéristiques suivantes :In the context of the invention, the term "man" must be understood in its most general sense, namely "human being", which includes men, women and children. Depending on the case, the gaseous mixture of the invention may comprise one or more of the following characteristics:
- il contient, en outre, de l'oxygène ou de l'oxygène et de l'azote.it contains, in addition, oxygen or oxygen and nitrogen.
- il est constitué uniquement d'oxygène et de protoxyde d'azote.it consists solely of oxygen and nitrous oxide.
- il est constitué uniquement d'oxygène, d'azote et de protoxyde d'azote, la proportion volumique en oxygène étant comprise entre 30 et 50%.it consists solely of oxygen, nitrogen and nitrous oxide, the volume proportion of oxygen being between 30 and 50%.
- il contient de préférence de 6 % à 14 % en volume de N2O.it preferably contains from 6% to 14% by volume of N 2 O.
- il est conditionné sous une pression supérieure à 2 bar au sein d'un récipient sous pression, en particulier à plus de 90 bar dans une bouteille de gaz.it is conditioned under a pressure greater than 2 bar in a pressure vessel, in particular more than 90 bar in a gas cylinder.
En d'autres termes, le mélange gazeux contenant de l'oxygène et du protoxyde d'azote selon l'invention est utilisable en tant que médicament inhalable destiné à prévenir une hyperalgésie chez l'homme.In other words, the gaseous mixture containing oxygen and nitrous oxide according to the invention is usable as an inhalable medicament for preventing hyperalgesia in humans.
Dit autrement encore, l'invention porte aussi sur l'utilisation d'un mélange gazeux selon l'invention pour fabriquer un médicament inhalable destiné à prévenir ou à diminuer une hyperalgésie chez l'homme, en particulier lorsque l' hyperalgésie est de type postopératoire, en particulier induite par au moins un opioïde.In other words, the invention also relates to the use of a gaseous mixture according to the invention for producing an inhalable medicament for preventing or reducing hyperalgesia in humans, in particular when the hyperalgesia is of the postoperative type. , in particular induced by at least one opioid.
Le mélange gazeux de l'invention est administré par inhalation au patient, par exemple au moyen d'un masque alimenté en gaz ou alors au moyen d'un ventilateur respiratoire et cette administration se fait durant la phase d'anesthésie dudit patient.The gaseous mixture of the invention is administered by inhalation to the patient, for example by means of a mask fed with gas or by means of a respiratory ventilator and this administration is done during the anesthesia phase of said patient.
L'invention porte donc aussi sur une méthode d'anesthésie d'un patient comprenant les étapes suivantes : a) administrer à un patient une substance anesthésique ou analgésique opioïde de manière à obtenir une anesthésie dudit patient par au moins ladite substance, b) maintenir le patient sous-anesthésie durant une durée donnée, en particulier durant au moins une partie de la phase diagnostic et/ou la phase opératoire dudit patient, c) administrer audit patient, avant, durant et/ou après l'étape b), un mélange gazeux d'O2 et de N2O selon l'invention, en particulier un mélange gazeux contenant de l'oxygène (O2) et du protoxyde d'azote (N2O) en une proportion de protoxyde d'azote comprise entre 5 et 15 % en volume.The invention thus also relates to a method of anesthesia of a patient comprising the following steps: a) administering to a patient an opioid anesthetic or analgesic substance so as to obtain anesthesia of said patient by at least said substance, b) maintain the patient under-anesthesia for a given duration, in particular during at least a part of the diagnosis phase and / or the operating phase of said patient, c) to administer to said patient, before, during and / or after step b), a gaseous mixture of O 2 and N 2 O according to the invention, in particular a gaseous mixture containing oxygen (O 2 ) and nitrous oxide (N 2 O) in a proportion of nitrous oxide included between 5 and 15% by volume.
Lorsqu'on souhaite administrer le mélange N2O/O2 de l'invention à un patient par l'intermédiaire d'un ventilateur, on pourra raccorder audit ventilateur soit une source de gaz contenant un mélange gazeux d'O2 et de N2O pré-conditionné selon l'invention, soit une source de N2O et une source d'oxygène et le mélange N2O/O2 dans les proportions
désirées selon l'invention se fera directement au sein dudit ventilateur par mélange desdits gaz.When it is desired to administer the mixture N 2 O / O 2 of the invention to a patient by means of a fan, it may be connected to said fan is a gas source containing a gas mixture of O 2 and N 2 O pre-conditioned according to the invention, a source of N 2 O and a source of oxygen and the mixture N 2 O / O 2 in the proportions Desired according to the invention will be directly within said fan by mixing said gases.
En d'autres termes, dans le deuxième cas, on définira le mélange gazeux voulu par réglage du ventilateur et c'est celui-ci qui fera automatiquement le mélange en prélevant les quantités de gaz pur venant de chacune des sources de gaz, telles des bouteilles de gaz ou un réseau de canalisations, ou les deux, qui lui sont raccordées.In other words, in the second case, the desired gas mixture will be defined by adjusting the fan and it is the latter which will automatically mix by taking the quantities of pure gas from each of the gas sources, such as gas cylinders or a network of pipes, or both, connected to it.
ExempleExample
L'efficacité du mélange gazeux selon l'invention a été évaluée en administrant à un mélange gazeux contenant 12.5 % en volume de protoxyde d'azote, 50% oxygène et le reste d'azote à un groupe de 20 personnes volontaires saines (test B) ayant reçu un anesthétique volatile, par exemple du remifentamyl, lors d'une recherche biomédicale impliquant un modèle de stimulation électrique pendant 2 h, reproduisant l'hyperalgésie post-opératoire.The effectiveness of the gaseous mixture according to the invention was evaluated by administering to a gaseous mixture containing 12.5% by volume of nitrous oxide, 50% oxygen and the rest of nitrogen to a group of 20 healthy volunteers (test B ) having received a volatile anesthetic, for example remifentamyl, during a biomedical research involving a model of electrical stimulation for 2 h, reproducing the postoperative hyperalgesia.
Le mélange gazeux N2O/O2/N2 est administré par inhalation aux personnes au moyen d'un masque respiratoire raccordé à une source de mélange gazeux, par exemple une bouteille de gaz contenant le mélange gazeux.The gas mixture N2O / O2 / N2 is administered by inhalation to persons by means of a breathing mask connected to a gas mixture source, for example a gas cylinder containing the gaseous mixture.
A titre comparatif, on a administré un placebo (gaz formé de 50% d'oxygène et de 50% d'azote) au même groupe de 20 personnes volontaires saines (test A) suivant strictement le même mode opératoire.For comparison, a placebo (a gas formed of 50% oxygen and 50% nitrogen) was administered to the same group of 20 healthy volunteers (test A) following strictly the same procedure.
Les personnes, lors du test A et du test B, sont soumises à des stimulations électriques de manière à évaluer leur niveau de sensibilité à la douleur.People in Test A and Test B undergo electrical stimulation to assess their level of sensitivity to pain.
L'hyperalgésie de ces personnes a été évaluée tout au long de la durée de la stimulation électrique (10 mesures pendant 2 heures).The hyperalgesia of these individuals was evaluated throughout the duration of the electrical stimulation (10 measurements for 2 hours).
Après comparaison des résultats obtenus, lors du test A, les volontaires sains présentent une plus grande sensibilité à la douleur que lors du test B, lorsqu'ils ont reçu le mélange N2O/O2 de l'invention.After comparing the results obtained, in test A, healthy volunteers have a greater sensitivity to pain than in test B, when they received the N2O / O2 mixture of the invention.
Grâce au mélange gazeux N2O/O2 de l'invention, on peut lutter efficacement contre l'effet néfaste d'hyperalgésie post-opératoire causée par les opioïdes, par administration aux voies aériennes du patient dudit mélange gazeux inhalable.Thanks to the gaseous mixture N 2 O / O 2 of the invention, one can effectively fight against the adverse effect of opioid-induced postoperative hyperalgesia, by administration to the patient's airways of said inhalable gas mixture.
Le mélange gazeux N2O/O2 de l'invention N2O/O2 peut être administré avant, durant et/ou après la phase d'anesthésie par opïoide, préférentiellement avant, durant et après la phase d'anesthésie.
The N 2 O / O 2 gas mixture of the invention N 2 O / O 2 may be administered before, during and / or after the opioid anesthesia phase, preferably before, during and after the anesthesia phase.
Claims
1. Mélange gazeux contenant de l'oxygène (O2) et du protoxyde d'azote (N2O), la proportion de protoxyde d'azote étant comprise entre 5 et 15 % en volume, pour une utilisation en tant que médicament inhalable destiné à prévenir ou à diminuer une hyperalgésie chez l'homme ou l'animal.1. Gaseous mixture containing oxygen (O 2 ) and nitrous oxide (N 2 O), the proportion of nitrous oxide being between 5 and 15% by volume, for use as an inhalable medicament intended to prevent or reduce hyperalgesia in humans or animals.
2. Mélange gazeux selon la revendication 1, caractérisé en ce que l' hyperalgésie est de type post-opératoire.2. Gaseous mixture according to claim 1, characterized in that the hyperalgesia is of the post-operative type.
3. Mélange gazeux selon l'une des revendications 1 ou 2, caractérisé en ce que l' hyperalgésie est de type post-opératoire induite par au moins un opioïde.3. Gas mixture according to one of claims 1 or 2, characterized in that the hyperalgesia is of the post-operative type induced by at least one opioid.
4. Mélange gazeux selon l'une des revendications précédentes, caractérisé en ce qu'il contient de 6% à 14 % de N2O.4. Gas mixture according to one of the preceding claims, characterized in that it contains from 6% to 14% of N 2 O.
5. Mélange gazeux selon l'une des revendications précédentes, caractérisé en ce qu'il est constitué uniquement d'oxygène et de protoxyde d'azote.5. Gas mixture according to one of the preceding claims, characterized in that it consists solely of oxygen and nitrous oxide.
6. Mélange gazeux selon l'une des revendications 1 à 4, caractérisé en ce qu'il contient, en outre, de l'azote.6. Gas mixture according to one of claims 1 to 4, characterized in that it further contains nitrogen.
7. Mélange gazeux selon l'une des revendications 1 à 4 ou 6, caractérisée en ce que le mélange gazeux est constitué uniquement d'oxygène, d'azote et de protoxyde d'azote, la proportion volumique en oxygène étant comprise entre 30 et 50%.7. Gaseous mixture according to one of claims 1 to 4 or 6, characterized in that the gaseous mixture consists solely of oxygen, nitrogen and nitrous oxide, the volume proportion of oxygen being between 30 and 50%.
8. Mélange gazeux selon l'une des revendications précédentes, caractérisé en ce qu'il contient de 6% à 14 % de N2O.8. Gaseous mixture according to one of the preceding claims, characterized in that it contains from 6% to 14% of N 2 O.
9. Utilisation selon l'une des revendications précédentes, caractérisé en ce qu'il est conditionné sous une pression supérieure à 2 bar au sein d'un récipient sous pression, en particulier sous une pression supérieure à 90 bar dans une bouteille de gaz. 9. Use according to one of the preceding claims, characterized in that it is conditioned under a pressure greater than 2 bar in a pressure vessel, in particular at a pressure greater than 90 bar in a gas cylinder.
10. Utilisation d'un mélange gazeux contenant de l'oxygène (O2) et du protoxyde d'azote (N2O) selon l'une des revendications 1 à 9, pour fabriquer un médicament inhalable destiné à prévenir ou à diminuer une hyperalgésie chez l'homme, en particulier une hyperalgésie de type post-opératoire induite par au moins un opioïde. 10. Use of a gas mixture containing oxygen (O 2 ) and nitrous oxide (N 2 O) according to one of claims 1 to 9, for producing an inhalable medicament for preventing or reducing a hyperalgesia in humans, particularly hyperalgesia of the postoperative type induced by at least one opioid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0754341A FR2914632B1 (en) | 2007-04-06 | 2007-04-06 | GAS MIXTURE BASED ON O2 OF N2O FOR PREVENTING OR REDUCING HYPERALGESIA |
| PCT/FR2008/050549 WO2008139078A2 (en) | 2007-04-06 | 2008-03-28 | Gaseous mixture containing o2 and n2o for preventing or reducing hyperalgesia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2131812A2 true EP2131812A2 (en) | 2009-12-16 |
Family
ID=38582151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08788075A Withdrawn EP2131812A2 (en) | 2007-04-06 | 2008-03-28 | Gaseous mixture containing o2 and n2o for preventing or reducing hyperalgesia |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100074966A1 (en) |
| EP (1) | EP2131812A2 (en) |
| CA (1) | CA2680016A1 (en) |
| FR (1) | FR2914632B1 (en) |
| WO (1) | WO2008139078A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2478356A (en) * | 2010-03-05 | 2011-09-07 | Esaturnus Nv | Nitrous oxide gas for use in preventing adhesion |
| EP3868361A1 (en) | 2020-02-20 | 2021-08-25 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Inhalable gaseous mixture for treating chronic pain in patients treated with opioids |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2929513B1 (en) * | 2008-04-02 | 2010-09-17 | Air Liquide | TREATMENT OF MIGRAINS WITHOUT AURA IN PREGNANT WOMEN BY INHALATION OF DIOXYGEN GASES. |
| FR2944969B1 (en) * | 2009-04-29 | 2011-08-26 | Air Liquide | USE OF N2O GASES IN THE TREATMENT OF CHRONIC PAIN |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2596989B1 (en) * | 1986-04-14 | 1990-05-18 | Air Liquide | RADIOSENSITIZATION PRODUCT FOR BIOLOGICAL TISSUES IN RADIOTHERAPY |
| FR2811910B1 (en) * | 2000-07-18 | 2003-01-24 | Air Liquide Sante France | PROCESS AND PLANT FOR DYNAMIC CONDITIONING OF GASES ESPECIALLY FOR MEDICAL USE |
| FR2858233B1 (en) * | 2003-07-30 | 2008-04-11 | Air Liquide Sante Int | INHALABLE GAS MEDICINE BASED ON XENON AND NITROGEN PROTOXIDE |
| US7503322B2 (en) * | 2003-09-12 | 2009-03-17 | Harris Michael F | Methods for the treatment of HIV and other viruses |
-
2007
- 2007-04-06 FR FR0754341A patent/FR2914632B1/en not_active Expired - Fee Related
-
2008
- 2008-03-28 EP EP08788075A patent/EP2131812A2/en not_active Withdrawn
- 2008-03-28 WO PCT/FR2008/050549 patent/WO2008139078A2/en not_active Ceased
- 2008-03-28 US US12/594,496 patent/US20100074966A1/en not_active Abandoned
- 2008-03-28 CA CA002680016A patent/CA2680016A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2008139078A2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2478356A (en) * | 2010-03-05 | 2011-09-07 | Esaturnus Nv | Nitrous oxide gas for use in preventing adhesion |
| EP3868361A1 (en) | 2020-02-20 | 2021-08-25 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Inhalable gaseous mixture for treating chronic pain in patients treated with opioids |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2914632A1 (en) | 2008-10-10 |
| WO2008139078A3 (en) | 2009-01-22 |
| CA2680016A1 (en) | 2008-11-20 |
| WO2008139078A2 (en) | 2008-11-20 |
| US20100074966A1 (en) | 2010-03-25 |
| FR2914632B1 (en) | 2009-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jovaiša et al. | Effects of ketamine on precipitated opiate withdrawal | |
| Brosnan et al. | Effects of remifentanil on measures of anesthetic immobility and analgesia in cats | |
| Yee et al. | Nitrous oxide inhalation sedation in dentistry: An overview of its applications and safety profile | |
| EP1541156B1 (en) | Inhalation medicament comprising argon and its use for the treatment of neurotoxicity | |
| Muzi et al. | The effects of premedication on inhaled induction of anesthesia with sevoflurane | |
| Zelinski et al. | A prolonged nitric oxide-dependent, opioid-mediated antinociceptive effect of hyperbaric oxygen in mice | |
| Gupta et al. | Evaluation of the efficacy of nitrous oxide inhalation sedation on anxiety and pain levels of patients undergoing endodontic treatment in a vital tooth: a prospective randomized controlled trial | |
| EP2131812A2 (en) | Gaseous mixture containing o2 and n2o for preventing or reducing hyperalgesia | |
| EP2851077A1 (en) | Use of nitrogen protoxide for the treatment of chronic dysfunctional pain | |
| JP2019123730A (en) | Dihydroetorphine to provide pain-relief and anesthesia | |
| Gueneron et al. | Effect of naloxone infusion on analgesia and respiratory depression after epidural fentanyl | |
| Ki et al. | Effect of dexamethasone gargle, intravenous dexamethasone, and their combination on postoperative sore throat: a randomized controlled trial | |
| Dandrea et al. | A comparison of breathing stimulants for reversal of synthetic opioid-induced respiratory depression in conscious rats | |
| Hellinga et al. | Oral Oxycodone‐Induced Respiratory Depression During Normocapnia and Hypercapnia: A Pharmacokinetic‐Pharmacodynamic Modeling Study | |
| Mets et al. | The role of catecholamines in cocaine toxicity: a model for cocaine “sudden death” | |
| Orden et al. | The effect of cannabidiol on sevoflurane minimum alveolar concentration reduction produced by morphine in rats | |
| Tackett et al. | Co-administration of naloxone and dexmedetomidine to simultaneously reverse acute effects of fentanyl and methamphetamine in rats | |
| JP6009353B2 (en) | Use of xenon for the treatment of hyperalgesia | |
| FR2914633A1 (en) | Gaseous mixture useful to prepare inhalable drug to prevent or reduce post-operative hyperalgesia induced by opioid in human, comprises oxygen and xenon | |
| WO2020221966A1 (en) | Inhalable gaseous mixture for treating chronic pain in patients receiving drugs from multiple therapeutic classes | |
| Lesage et al. | Low-dose fentanyl-midazolam combination improves sevoflurane induction in adults | |
| Emmanouil | The pharmacology, physiology and clinical application in dentistry of nitrous oxide | |
| Lewis et al. | Nalfurafine reverses fentanyl-induced muscle rigidity and respiratory depression without affecting sedation in rats: decoupling respiration from sedation | |
| FR3017052A1 (en) | GASEOUS MIXTURE NO / HE WITH BACTERICIDE ACTION | |
| FR3123802A3 (en) | Gas mixture based on argon and helium usable in case of ischemic stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20091106 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20121002 |